Neurology News

The FDA has approved a supplemental new drug application for Rexulti for the treatment of agitation associated with dementia due to Alzheimer’s disease.

You might remember our earlier blog post on the Physician Self-Referral Law, aka the Stark Law.

SAN DIEGO — “Now more than ever,” physicians need to manage opioid use disorder with pharmacological treatment in the primary care setting, according to a speaker at the ACP Internal Medicine Meeting.

Obstructive sleep apnea had a significant effect on perceived problems with cognitive function in women with multiple sclerosis, according to study results published in Multiple Sclerosis Journal.

BOSTON — The majority of patients with relapsing-remitting MS who took ocrelizumab had no evidence of disease activity for 4 years, according to a study presented at the American Academy of Neurology annual meeting.

A patient’s duration of Parkinson’s disease can affect visual field sensitivity, according to a poster presented at the North American Neuro-Ophthalmology Society meeting.

Physical wellness and social functioning were adversely affected in adults who were aware of abnormal involuntary movements indicative of tardive dyskinesia, according to research in the Journal of Patient-Reported Outcomes.

Physical wellness and social functioning were adversely affected in adults who were aware of abnormal involuntary movements indicative of tardive dyskinesia, according to research in the Journal of Patient-Reported Outcomes.

SEATTLE — Among men aged at least 40 years who experienced a fracture, most with subsequent fractures in the next 2 years had cardiometabolic comorbidities and used medications linked to increased fall risk, according to researchers.

The FDA has granted 510(k) clearance to Cumulus Neuroscience for its dry-sensor electroencephalogram headset, for self-directed use by adolescents and adults at home or at health care facilities.